Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Clinical Trials
741
Trial Phases
5 Phases
Drug Approvals
5
Clinical Trials
Distribution across different clinical trial phases (658 trials with phase data)• Click on a phase to view related trials
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 290000
- Registration Number
- NCT07105228
- Locations
- 🇺🇸
Regeneron Research Site, Tarrytown, New York, United States
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2000
- Registration Number
- NCT07015905
- Locations
- 🇺🇸
Phoenix Clinical Research, Tamarac, Florida, United States
Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT06975787
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06970405
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
- Conditions
- Melanoma
- Interventions
- Drug: Fianlimab+cemiplimab
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06848088
- Locations
- 🇺🇸
Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸South Texas Oncology And Hematology, San Antonio, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 70
- Next
News
Sensei Biotherapeutics Advances VISTA-Targeting Cancer Therapy with Q2 2025 Results and ESMO Presentation
Sensei Biotherapeutics reported Q2 2025 financial results with $28.6 million in cash to fund operations into Q2 2026, while advancing its lead cancer immunotherapy solnerstotug.
FDA Issues Second Rejection for Regeneron's Lymphoma Therapy Odronextamab Due to Manufacturing Issues
The FDA declined to approve Regeneron's lymphoma therapy odronextamab for the second time, citing manufacturing issues at a third-party Catalent facility rather than safety or efficacy concerns.
Sensei Biotherapeutics to Present Phase 1 Data on Novel VISTA-Targeting Cancer Therapy at ESMO 2025
Sensei Biotherapeutics will present clinical data from the Phase 1 dose expansion cohort of solnerstotug, a pH-selective anti-VISTA antibody, at ESMO Congress 2025 in Berlin.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
Hengrui and Kailera's Dual GLP-1/GIP Obesity Drug Achieves 18% Weight Loss in Phase 3 Trial
Hengrui Pharma and Kailera Therapeutics' dual-acting obesity drug HRS9531 demonstrated 18% weight loss in a Phase 3 trial in China, significantly outperforming placebo by 16%.
Health Canada Extends Evkeeza Approval to Infants as Young as 6 Months for Rare Cholesterol Disorder
Health Canada has extended approval of Evkeeza (evinacumab) to treat children as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), a devastating inherited cholesterol disorder.
Regeneron and BioNTech Advance Phase 2 Trial Combining Cancer Vaccine BNT116 with Cemiplimab for Advanced NSCLC
Regeneron Pharmaceuticals and BioNTech SE are conducting a Phase 2 clinical trial evaluating the combination of investigational cancer vaccine BNT116 with cemiplimab versus cemiplimab monotherapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50%.
IL-2 Inhibitor Pipeline Expands with 20+ Companies Developing 22+ Therapeutic Candidates
DelveInsight's 2025 pipeline report reveals over 20 pharmaceutical companies are actively developing 22+ interleukin-2 inhibitor drugs across various clinical stages.
FDA Publishes Over 200 Drug Rejection Letters in Historic Transparency Initiative
The FDA published more than 200 Complete Response Letters (CRLs) from 2020-2024 for drug applications that were initially rejected but later approved, marking a significant step toward increased regulatory transparency.
EPO and UPC Reach Opposite Conclusions on Amgen's PCSK9 Antibody Patent Validity
The European Patent Office (EPO) Opposition Division upheld Amgen's PCSK9 antibody patent EP 3666797, finding it inventive, while the Unified Patent Court (UPC) Central Division revoked the same patent for lacking inventive step.